Shares of Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.99 and traded as high as $2.54. Microbot Medical shares last traded at $2.49, with a volume of 903,804 shares traded.
Analyst Ratings Changes
MBOT has been the topic of several research reports. Wall Street Zen raised shares of Microbot Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 price target on shares of Microbot Medical in a research report on Thursday, April 10th.
Read Our Latest Research Report on MBOT
Microbot Medical Stock Up 4.0%
The firm's 50-day moving average price is $2.55 and its 200-day moving average price is $2.02. The company has a market cap of $94.59 million, a P/E ratio of -4.00 and a beta of 1.13.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. As a group, analysts forecast that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Trading of Microbot Medical
Several hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical in the first quarter valued at approximately $57,000. Virtu Financial LLC bought a new stake in Microbot Medical during the 1st quarter worth approximately $42,000. Renaissance Technologies LLC bought a new stake in Microbot Medical during the 4th quarter worth approximately $118,000. Finally, Geode Capital Management LLC increased its holdings in Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares during the period. Institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Recommended Stories
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
